<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704404</url>
  </required_header>
  <id_info>
    <org_study_id>0091</org_study_id>
    <nct_id>NCT01704404</nct_id>
  </id_info>
  <brief_title>7 Days of TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD−4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects
      with Chronic Obstructive Pulmonary Disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second)</measure>
    <time_frame>From baseline to day 7</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Cmax</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Tmax</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma Half-life</measure>
    <time_frame>From baseline to day 7</time_frame>
    <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Dose 1 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>44 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>88 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>175 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>350 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6 TD-4208</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>700 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208</intervention_name>
    <arm_group_label>Dose 1 TD-4208</arm_group_label>
    <arm_group_label>Dose 2 TD-4208</arm_group_label>
    <arm_group_label>Dose 3 TD-4208</arm_group_label>
    <arm_group_label>Dose 4 TD-4208</arm_group_label>
    <arm_group_label>Dose 5 TD-4208</arm_group_label>
    <arm_group_label>Dose 6 TD-4208</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is a male or female between the ages of 40 and 75 years (inclusive, at
             randomization).

          2. Subject:

               -  Has an FEV1/FVC (forced expiratory volume in 1 second/forced vital capacity) &lt;0.7
                  at screening; and

               -  Has a post-bronchodilator FEV1 at screening of between 30% and 80% (inclusive) of
                  the predicted normal value.

          3. Subject demonstrates at screening at least a 120 mL increase in FEV1 within 1 hour of
             receiving 500 µg of ipratropium bromide from a PARI LC Sprint® nebulizer.

          4. Females of non-childbearing potential. All male subjects must agree to use a highly
             effective method of birth control with partners of childbearing potential during the
             study and for 1 month after completion of study dosing.

          5. Subject (or care giver) is able to properly prepare and administer study medication.

          6. Subject is willing and able to give written informed consent to participate.

        Exclusion Criteria:

          1. Subject has had a COPD exacerbation or lung infection within 6 weeks before
             randomization.

          2. Subject has had an initiation of treatment, or a change in dose, of an inhaled or oral
             corticosteroid, or long-acting beta2 agonist (LABA), or long-acting muscarinic
             antagonist (LAMA) within 4 weeks before the qualifying ipratropium bromide response
             test.

          3. Subject is taking daily maintenance inhaled/systemic corticosteroids (&gt;1000 μg of
             fluticasone propionate equivalent or ≥10 mg prednisone).

          4. Subject has an uncontrolled hematologic, immunologic, renal, neurologic, hepatic,
             endocrine, or other disease or condition based on information gathered from the
             medical history, physical examination, or laboratory findings that might place the
             subject at undue risk or potentially compromise the results or interpretation of the
             study.

          5. Subject has a history of significant cerebrovascular disease, coronary artery disease,
             or cardiac arrhythmias. Subject has a history (or family history) of congenital
             prolonged QTc (corrected QT interval) syndrome or has an abnormal clinically
             significant electrocardiogram (ECG) at screening, including QTcB (QT interval
             corrected for heart rate using Bazett's formula) value &gt;450 msec (males) or &gt;470 msec
             (females); or shows evidence of clinically significant rhythm abnormality.

          6. Subject has a known hypersensitivity to TD-4208 or similar drug class.

          7. Subject has a history of alcoholism or drug abuse within 2 years prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Glenn Crater, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma, US, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P3 Research Ltd</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <results_first_submitted>January 17, 2017</results_first_submitted>
  <results_first_submitted_qc>January 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 13, 2017</results_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Long acting muscarinic antagonist</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment 1</title>
          <description>Placebo, 44 µg, 88 µg, 350 µg, 700 µg</description>
        </group>
        <group group_id="P2">
          <title>Treatment 2</title>
          <description>Placebo, 22 µg, 88 µg, 350 µg, 700 µg</description>
        </group>
        <group group_id="P3">
          <title>Treatment 3</title>
          <description>Placebo, 22 µg, 88 µg, 175 µg, 700 µg</description>
        </group>
        <group group_id="P4">
          <title>Treatment 4</title>
          <description>22 µg, 44 µg, 175 µg, 700 µg</description>
        </group>
        <group group_id="P5">
          <title>Treatment 5</title>
          <description>22 µg, 44 µg, 175 µg, 350 µg</description>
        </group>
        <group group_id="P6">
          <title>Treatment 6</title>
          <description>Placebo, 44 µg, 88 µg, 175 µg, 350 µg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>All subjects received Placebo and 4 of 6 TD-4208 dose levels:
TD-4208 - 22 µg TD-4208 - 44 µg TD-4208 - 88 µg TD-4208 - 175 µg TD-4208 - 350 µg TD-4208 - 700 µg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second)</title>
        <time_frame>From baseline to day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose 1 TD-4208</title>
            <description>22 µg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>Dose 2 TD-4208</title>
            <description>44 µg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Dose 3 TD-4208</title>
            <description>88 µg
TD-4208</description>
          </group>
          <group group_id="O4">
            <title>Dose 4 TD-4208</title>
            <description>175 µg
TD-4208</description>
          </group>
          <group group_id="O5">
            <title>Dose 5 TD-4208</title>
            <description>350 µg
TD-4208</description>
          </group>
          <group group_id="O6">
            <title>Dose 6 TD-4208</title>
            <description>700 µg
TD-4208</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 7 in Trough FEV1 (Forced Expiratory Volume in 1 Second)</title>
          <units>FEV1 (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="39"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.2" spread="19.21"/>
                    <measurement group_id="O2" value="92.8" spread="20.25"/>
                    <measurement group_id="O3" value="113.1" spread="19.55"/>
                    <measurement group_id="O4" value="151.9" spread="19.99"/>
                    <measurement group_id="O5" value="132.2" spread="19.02"/>
                    <measurement group_id="O6" value="119.4" spread="19.54"/>
                    <measurement group_id="O7" value="37.8" spread="16.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Cmax</title>
        <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
        <time_frame>From baseline to day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose 1 TD-4208</title>
            <description>22 µg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>Dose 2 TD-4208</title>
            <description>44 µg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Dose 3 TD-4208</title>
            <description>88 µg
TD-4208</description>
          </group>
          <group group_id="O4">
            <title>Dose 4 TD-4208</title>
            <description>175 µg
TD-4208</description>
          </group>
          <group group_id="O5">
            <title>Dose 5 TD-4208</title>
            <description>350 µg
TD-4208</description>
          </group>
          <group group_id="O6">
            <title>Dose 6 TD-4208</title>
            <description>700 µg
TD-4208</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0125" spread=".00627"/>
                    <measurement group_id="O2" value=".0224" spread=".00864"/>
                    <measurement group_id="O3" value=".0526" spread=".0214"/>
                    <measurement group_id="O4" value=".114" spread=".0488"/>
                    <measurement group_id="O5" value=".243" spread=".104"/>
                    <measurement group_id="O6" value=".577" spread=".261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Tmax</title>
        <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
        <time_frame>From baseline to day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dose 1 TD-4208</title>
            <description>22 µg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>Dose 2 TD-4208</title>
            <description>44 µg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Dose 3 TD-4208</title>
            <description>88 µg
TD-4208</description>
          </group>
          <group group_id="O4">
            <title>Dose 4 TD-4208</title>
            <description>175 µg
TD-4208</description>
          </group>
          <group group_id="O5">
            <title>Dose 5 TD-4208</title>
            <description>350 µg
TD-4208</description>
          </group>
          <group group_id="O6">
            <title>Dose 6 TD-4208</title>
            <description>700 µg
TD-4208</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax</title>
          <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="40"/>
                <count group_id="O6" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".233" spread=".217"/>
                    <measurement group_id="O2" value=".233" spread="0.200"/>
                    <measurement group_id="O3" value="0.233" spread="0.200"/>
                    <measurement group_id="O4" value="0.233" spread="0.200"/>
                    <measurement group_id="O5" value="0.233" spread="0.217"/>
                    <measurement group_id="O6" value="0.233" spread="0.200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Plasma Half-life</title>
        <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
        <time_frame>From baseline to day 7</time_frame>
        <population>The number of subjects reported for plasma half lives are based on the actual evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose 1 TD-4208</title>
            <description>22 µg
TD-4208</description>
          </group>
          <group group_id="O2">
            <title>Dose 2 TD-4208</title>
            <description>44 µg
TD-4208</description>
          </group>
          <group group_id="O3">
            <title>Dose 3 TD-4208</title>
            <description>88 µg
TD-4208</description>
          </group>
          <group group_id="O4">
            <title>Dose 4 TD-4208</title>
            <description>175 µg
TD-4208</description>
          </group>
          <group group_id="O5">
            <title>Dose 5 TD-4208</title>
            <description>350 µg
TD-4208</description>
          </group>
          <group group_id="O6">
            <title>Dose 6 TD-4208</title>
            <description>700 µg
TD-4208</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half-life</title>
          <description>Day 1: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, and 6 hours.
Day 7: 15 minutes pre-dose, post-dose at 15 and 30 minutes, 1, 2, 3, 4, 6, 8, 12 and 24 hours.</description>
          <population>The number of subjects reported for plasma half lives are based on the actual evaluable PK data.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="25.1" spread="7.89"/>
                    <measurement group_id="O6" value="23.0" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>13 weeks</time_frame>
      <desc>The Participant Flow shows the # of subjs in each of the 6 treatment sequences (each sequence has 4 treatments; 4/6 study drug doses and placebo) as instructed by CTgov for complex crossover designs. The Number of Participants at Risk, instead, shows the # of subjs exposed to each of the 6 doses of study drug and placebo. Also, some subjs did not complete all of the doses in their treatment sequence. The # of subjs in each sequence is not related to the # of subjs in each dose level therefore.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dose 1 TD-4208</title>
          <description>22 µg
TD-4208</description>
        </group>
        <group group_id="E2">
          <title>Dose 2 TD-4208</title>
          <description>44 µg
TD-4208</description>
        </group>
        <group group_id="E3">
          <title>Dose 3 TD-4208</title>
          <description>88 µg
TD-4208</description>
        </group>
        <group group_id="E4">
          <title>Dose 4 TD-4208</title>
          <description>175 µg
TD-4208</description>
        </group>
        <group group_id="E5">
          <title>Dose 5 TD-4208</title>
          <description>350 µg
TD-4208</description>
        </group>
        <group group_id="E6">
          <title>Dose 6 TD-4208</title>
          <description>700 µg
TD-4208</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Glenn Crater, Head of Clinical Development &amp; Medical Affairs</name_or_title>
      <organization>Theravance Biopharma US, Inc.</organization>
      <phone>650-808-6000</phone>
      <email>GCrater@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

